The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2024-03-27

Name:	ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details) € in Millions				3 Months Ended	12 Months Ended
	Jan. 15, 2024	Oct. 11, 2023	Sep. 29, 2023	Dec. 31, 2023	Dec. 31, 2024 EUR (€) entity	Dec. 31, 2023
General principles and statement of compliance
Number of entities being consolidated \| entity					2
Hepalys Pharma, Inc
General principles and statement of compliance
Proportion of ownership interest	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%
Inventiva Inc.
General principles and statement of compliance
Percent of ownership interest					100.00%
Non-controlling interest \| €					€ 0.0